Olaparib (AZD2281, Ku-0059436)

目录号:S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。

规格 价格 库存 购买数量  
RMB 745.41 现货
RMB 571.54 现货
RMB 1219.52 现货
RMB 3019.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献80篇:

客户使用该产品的18个实验数据:

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Olaparib (AZD2281, KU0059436)是选择性的PARP1/2抑制剂,IC50为5 nM/1 nM,其对PARP1/2的作用比对Tankyrase-1效果高300倍。
特性 Olaparib是第一批PARP抑制剂之一。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
体外研究

Olaparib是PARP抑制剂,也作用于BRCA1或BRCA2突变。Olaparib对端锚(聚合)酶-1作用效果不大,IC50值大于。Olaparib浓度为30-100 nM作用于SW620细胞,使PARP-1失活。与BRCA1和BRCA2充足细胞系(Hs578T,MDA-MB-231,T47D)相比,BRCA1缺陷细胞系(MDA-MB-463和HCC1937)对Olaparib过分敏感[1] Olaparib抑制PARP,阻断碱基切除修复,导致KB2P细胞对Olaparib强烈敏感。结果导致在DNA复制时由单链断裂转变为双链断裂,由此激活BRCA2依赖的重组途径。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NULnepJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PRNFQh\A>? M1z3SGlEPTB;NT63NFUhKM7:TTC= MkWyNVg2PTl4MUO=
KP6.3 M2rOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe0JIQ> MmLLTWM2OD1zMD60Nlgh|ryPIB?= NFjhXWYyQDV3OU[xNy=>
KP7.7 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO1eIZXPCCm MojSTWM2OD13NzDuUUA> M{DQPVE5PTV7NkGz
KB2P3.4 NXi4T|RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3OEBl MUTJR|UxRTF{NDDNJC=> MknnNVg2PTl4MUO=
KB2P1.21 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O4eVQh\A>? NH3DNZlKSzVyPUi5NFchdk1i Mlu1NVg2PTl4MUO=
U373-MG M{Xnc2N6fG:2b4jpZ{BCe3OjeR?= M1LPcVEh|ryPIB?= M1HUUFI1KGh? MVLJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M{D5fVE5QTV2N{Gy
T98G NIm5T49EgXSxdH;4bYMhSXO|YYm= NYrxXpJzOSEQvF2g NH76XZozPCCq NFK0[2hKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MoLENVg6PTR5MUK=
U87-MG NVnZfpExS3m2b4TvfIlkKEG|c3H5 NG\1VlEyKM7:TTC= NI\4WGkzPCCq MWPJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M3q0ZVE5QTV2N{Gy
UVW MWjDfZRwfG:6aXOgRZN{[Xl? NVT4Z3VOPTByIH7N NW\uRotqOjRiaB?= MkLOTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NFXEZ40yQDl3NEexNi=>
HeLa NVjoepRJTnWwY4Tpc44hSXO|YYm= NIXkSm42ODBibl2= NYPaWFZrPCCq M4X4fGNifXOnczDhJI1w\GW|dDDk[YxigSCrbjDy[YpwcW6rbnegc4YhemGmaXH0bY9vNWmwZIXj[YQhTE6DIHLy[YFsew>? MYCxPFk2PDdzMh?=
HeLa NFTLU3JHfW6ldHnvckBCe3OjeR?= NFK5eHIyKM7:TTC= NFyyVHEzPCCq NH\BboVGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= NUHUfGZ7OTh7NUS3NVI>
T98G MonGSpVv[3Srb36gRZN{[Xl? M4HtcVEh|ryPIB?= MnXyNlQhcA>? MX\FcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? NF3FdVAyQDl3NEexNi=>
L3 MWjDfZRwfG:6aXOgRZN{[Xl? NGXhNVk2KM7:TTC= M{\jflk3KGh? MWrEUXNQ M4HsUXNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M2C5RVIxOTJ2NEW5
Granta-519 Ml;GR5l1d3SxeHnjJGF{e2G7 Mn25OUDPxE1i MXu5OkBp MmnzSG1UVw>? NFXpV4JUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MWiyNFEzPDR3OR?=
BT M4TmXmN6fG:2b4jpZ{BCe3OjeR?= MoLhOUDPxE1i M2rrPVk3KGh? NX3CNGJ1TE2VTx?= NXHGWINOW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MlqxNlAyOjR2NUm=
UPN2 M2jybmN6fG:2b4jpZ{BCe3OjeR?= NGLKN482KM7:TTC= MlqwPVYhcA>? MWTEUXNQ NFXxZ3dUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MnnMNlAyOjR2NUm=
HBL-2 NYTHU2h6S3m2b4TvfIlkKEG|c3H5 NEW4RZg2KM7:TTC= NVnw[mxsQTZiaB?= M3PTbmROW09? M1y5enNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NYf5Ro9vOjBzMkS0OVk>
JVM-2 NGLvVo1EgXSxdH;4bYMhSXO|YYm= MkTROUDPxE1i M{TZblk3KGh? NFTre5BFVVOR MXTTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NIfxTZgzODF{NES1PS=>
Z138 NY\OW2RYS3m2b4TvfIlkKEG|c3H5 NFHVem02KM7:TTC= NV7vWo05QTZiaB?= NWXw[2ZFTE2VTx?= MVHTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NVfHRm1COjBzMkS0OVk>
RWPE M4rGd2lvfmG|aY\lJGF{e2G7 NXH2dnJJOjVizszN NVrlfohvPDhiaB?= MXzEUXNQ M4jZXXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MkG3NlE2PzV6NkW=
VCaP NXzhO|h[UW64YYPpeoUhSXO|YYm= NUnue4pXOjVizszN NUf4epYxPDhiaB?= NGXsc4tFVVOR M4rSfXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MVyyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells NV;kblhrS3m2b4TvfIlkKEG|c3H5 M{nFTVIvPSEQvF2= NEPoSHIzOCCq NUPqeWFHW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MoHpNlM{PTV2OEm=
Mouse ATM−/− ES Cells NUPleGx7S3m2b4TvfIlkKEG|c3H5 MlvlNk42KM7:TR?= NUXEW4xYOjBiaB?= NHvEflBUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> Ml7SNlM{PTV2OEm=
H1650 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDjR3FROjBizszN NVzOV4F1OTR2IHi= NXL1R4FPUUN3ME2xOU41PyEQvF2= M2HBWlI{OjN7OEC5
H1650PTEN+ Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHTPJR{OjBizszN MVKxOFQhcA>? NUXUS3BGUUN3ME21NE45OyEQvF2= Mm\RNlMzOzl6MEm=
PC-9 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LzWVIxKM7:TR?= NX[5T2xPOTR2IHi= NXTTSZNNUUN3ME21Mlg5KM7:TR?= NEHtXYMzOzJ|OUiwPS=>
PC-9PTEN− Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsb3VwOjBizszN NYm5U2dSOTR2IHi= NHzXW4JKSzVyPU[uOVIh|ryP M1H2cFI{OjN7OEC5
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vwXlUh\GG7 NULqWGlCUUN3ME22Mlkh|ryP NEnD[20zOzd4MES5Oi=>
MDA-MB-468 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi1JIRigQ>? M1nLWmlEPTB;NT6wJO69VQ>? MX[yN|c3ODR7Nh?=
BT20 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13uO|Uh\GG7 NVXQ[FBpUUN3ME23Mlch|ryP MYGyN|c3ODR7Nh?=
HCC1143 NIfzOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zibFUh\GG7 MkfmTWM2OD1zMT6xJO69VQ>? NYf4SZlOOjN5NkC0PVY>
HCC1937 NGfDUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfIXWhyPSCmYYm= NXK0b4VSUUN3ME2xNk43KM7:TR?= M37XclI{PzZyNEm2
Hs578t NHjIcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXZblZbPSCmYYm= M4[wZWlEPTB;NT62JO69VQ>? M3jpUFI{PzZyNEm2
Hs578t(si) NEPEVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr5WVQ2KGSjeR?= NVPlU4lUUUN3ME23MlUh|ryP NUHJUpZGOjN5NkC0PVY>
BT474 M{Lm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS1JIRigQ>? MXLJR|UxRTF7Lkig{txO M3HTNFI{PzZyNEm2
JIMT1 NUHoWotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XSSVUh\GG7 Mk\2TWM2OD15Lkeg{txO M2LHPVI{PzZyNEm2
SKBR3 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS1JIRigQ>? MkTBTWM2OD1zMT6xJO69VQ>? NFzkVIEzOzd4MES5Oi=>
SUM159 NHj2eVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWG1JIRigQ>? NWDQTIhkUUN3ME20MlIh|ryP NFLpU48zOzd4MES5Oi=>
CAMA1 M3XsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PKVFUh\GG7 NXPQcHY2UUN3ME2xOU45KM7:TR?= Mk\4NlM4PjB2OU[=
MCF7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqwS2Q2KGSjeR?= NYH5dZlQUUN3ME21Mlgh|ryP NIruPWwzOzd4MES5Oi=>
T47D M4\3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS1JIRigQ>? NGHnTVFKSzVyPUmuOkDPxE1? NYC3N3drOjN5NkC0PVY>
HCT116 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljwNVAxKM7:TR?= MoH6OFghcA>? M3XjZWROW09? M4DkeGlEPTB;Mj61JO69VSB? NWe3Ro1JOjR3N{e5OFE>
SW1116 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOwZ4pHOTByIN88US=> MWO0PEBp M1HTVmROW09? MknBTWM2OD1zMECg{txO NWDDdIhCOjR3N{e5OFE>
HT29 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGxfmhWOTByIN88US=> MYG0PEBp NYTZWmR6TE2VTx?= NUK2PFRFUUN3ME2xOE44KM7:TR?= NGrmeGszPDV5N{m0NS=>
LoVo NITiXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jWTlExOCEQvF2= NWPsS4c4PDhiaB?= M{HWNGROW09? M1PtUGlEPTB;MUOuOEDPxE1? MWSyOFU4Pzl2MR?=
HCT-15 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNFAh|ryP MVG0PEBp NH2yVplFVVOR Mor2TWM2OD1zMDFOwG0> MYOyOFU4Pzl2MR?=
SW48 NYC0WXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexNFAh|ryP MVG0PEBp NUi4N|lqTE2VTx?= NUTCdGdzUUN3ME25MlUh|ryP MWCyOFU4Pzl2MR?=
C-1 NH75THpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUWXcyODBizszN MVi0PEBp M4TZc2ROW09? MUjJR|UxRTdwNjFOwG0> NUPIe4c2OjR3N{e5OFE>
RKO NEDjZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxNFAh|ryP NXnXVWRCPDhiaB?= Ml3XSG1UVw>? M{PiWGlEPTB;NT65JO69VQ>? Mk\kNlQ2Pzd7NEG=
HCT116 M{jwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCxNVAxKM7:TR?= NH7PcW41QCCq M1LGRWROW09? Mo\LVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MofRNlQ2Pzd7NEG=
SW1116 M1\SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7qZWYyODBizszN NHjLSZY1QCCq NEDrUW1FVVOR NHTITWNRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NFHLWmUzPDV5N{m0NS=>
HT29 NUXxPFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NImxSIIyODBizszN MnjwOFghcA>? MneySG1UVw>? MU\Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh Ml;tNlQ2Pzd7NEG=
LoVo NVrlR5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj1NVAxKM7:TR?= M{PtOlQ5KGh? NHX5eZNFVVOR M{DWb3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NXrC[|JYOjR3N{e5OFE>
SW48 M3Lncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\zc4UyODBizszN NGLQfFA1QCCq M4XlNWROW09? NI\jOXpRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MnHDNlQ2Pzd7NEG=
C-1 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7aNVAxKM7:TR?= NUDkc2piPDhiaB?= MlS4SG1UVw>? Mnj5VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MoHtNlQ2Pzd7NEG=
RKO M1jJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPNVAxKM7:TR?= NI\2e4g1QCCq NInGOlBFVVOR MXLQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NHLCbG4zPDV5N{m0NS=>
HCT116 NWntOog6TnWwY4Tpc44hSXO|YYm= NWnSTHRNOTBibl2= MX2xNkBp NIL0TpNFVVOR MVjJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? NIThVI8zPDV5N{m0NS=>
HT29 NUjCe3l3TnWwY4Tpc44hSXO|YYm= MVWxNEBvVQ>? NFrzc5IyOiCq MkfjSG1UVw>? M4PuRmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= NHHoZ2IzPDV5N{m0NS=>
TE-6 NEHCW4hHfW6ldHnvckBCe3OjeR?= M1TDfFUh|ryPIB?= MVOxNkBp MoXESG1UVw>? M3r3R2lv\HWlZYOgS|IwVSCjcoLld5Q> M1;GZlI1OjF7MU[0
TE-6 NVnHZXpXTnWwY4Tpc44hSXO|YYm= M3HNZVUh|ryPIB?= NU\FdIJtOjRiaB?= MnnzSG1UVw>? MW\JcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq NUSySXBrOjR{MUmxOlQ>
Hep3B NWTEcW9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fwRlQxKM7:TTC= M4LMeVczKGh? MofnSG1UVw>? NXLVb25vW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? MoizNlUxPzJ5NUK=
Huh7 NGPJWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG0NEDPxE1i MWG3NkBp MWjEUXNQ NF;kd5NUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M4HtSlI2ODd{N{Wy
Hep3B NUTQcHNMTnWwY4Tpc44hSXO|YYm= MWS0NEDPxE1i NGiwN5QzPCCq MVLEUXNQ MlziTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NWLy[44yOjVyN{K3OVI>
Huh7 NWn5NHNRTnWwY4Tpc44hSXO|YYm= M3\RZVQxKM7:TTC= MWeyOEBp NXS3d2NiTE2VTx?= M3TjdGlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= MoK2NlUxPzJ5NUK=
Hep3B MUXGeY5kfGmxbjDBd5NigQ>? MoHmOFAh|ryPIB?= NYDXVoZkOjRiaB?= MmjOSG1UVw>? MVfJcoR2[2W|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF? MWeyOVA4Ojd3Mh?=
Huh7 NIXiVndHfW6ldHnvckBCe3OjeR?= MV[0NEDPxE1i MlfaNlQhcA>? MYrEUXNQ NGTHTYdKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= M4X1[FI2ODd{N{Wy
SGC-7901 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe3V44{OMLizszN M1;SeFQ5KGh? MVfEUXNQ NV7ONWRoSmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NWjYWlhlOjV5NkewO|Y>
COLO-800 NF[xfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\2XGlEPTB;MD60OFE3PCEQvF2= MXfTRW5ITVJ?
EoL-1- NVHqOohtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHwTWM2OD1yLkW2OFQ3KM7:TR?= MVPTRW5ITVJ?
NCI-H209 NUfHcGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInLWmZKSzVyPUCuPVE2PTZizszN MXTTRW5ITVJ?
ES1 M{m1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i4SWlEPTB;MT6xNVQxQCEQvF2= NUDKXnZDW0GQR1XS
NKM-1 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jM[mlEPTB;MT6yOVM1PyEQvF2= NHjLfoJUSU6JRWK=
NTERA-S-cl-D1 MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\vWGlEPTB;MT6zN|M1OSEQvF2= MV;TRW5ITVJ?
MHH-ES-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13DUGlEPTB;MT62NlA3PyEQvF2= NUS0RWJXW0GQR1XS
ES8 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwN{K0NVQh|ryP NGTnV21USU6JRWK=
NCI-H720 NXLtPIEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD1{LkKwOlk6KM7:TR?= MnG3V2FPT0WU
EW-3 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fESGlEPTB;Mj6yO|U{PCEQvF2= NH22eVJUSU6JRWK=
D-566MG NIfjRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[4XWlEPTB;Mj60OFU3QCEQvF2= MnfuV2FPT0WU
697 NUHZZ4pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwOESxO|Mh|ryP MnfHV2FPT0WU
ES5 NGXEOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjlc5VwUUN3ME2yMlg5OTh7IN88US=> MoXtV2FPT0WU
COLO-684 NX\WRW1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlraTWM2OD1|LkWxOlk3KM7:TR?= MlzOV2FPT0WU
ML-2 NH3LZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTNwNkCwOVgh|ryP NHTOV4pUSU6JRWK=
MC-IXC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf5SXMyUUN3ME2zMlY{Ozl|IN88US=> NVLBOW5LW0GQR1XS
DB NFfsN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwNkW0OFgh|ryP NGHPOXhUSU6JRWK=
HCC2218 NXfLT2l4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf1emRKSzVyPUOuO|MyODNizszN MVTTRW5ITVJ?
NCI-H510A NUPCWYQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwOEK3NlQh|ryP MVjTRW5ITVJ?
NCI-H526 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwOE[5OVgh|ryP NUjkdHdWW0GQR1XS
MV-4-11 NX6yeVFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\2TWM2OD12LkGzN|M1KM7:TR?= MoLwV2FPT0WU
PA-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYZm5CUUN3ME20MlI2OjlizszN NVOxWJBGW0GQR1XS
EW-22 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD12LkO1PFYh|ryP MVzTRW5ITVJ?
KASUMI-1 NIHrTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vzNmlEPTB;ND60NFExQSEQvF2= M4\KS3NCVkeHUh?=
LU-139 NV3QeotnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHmWldKSzVyPUSuO|U5OjlizszN M2PGcHNCVkeHUh?=
SBC-1 NUKxTFZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTRwOEC5NFgh|ryP M2\sUnNCVkeHUh?=
H4 M3TofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq2TWM2OD12Lki5OFQ{KM7:TR?= NEPDdZNUSU6JRWK=
EW-11 M1fPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTrZ25mUUN3ME21MlA5ODd{IN88US=> MnnCV2FPT0WU
NBsusSR M1faWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WxPWlEPTB;NT6xNlA2PSEQvF2= Mn\xV2FPT0WU
RPMI-8226 MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn1R5VDUUN3ME21MlE2OjR2IN88US=> MYfTRW5ITVJ?
DEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:wfZFVUUN3ME21MlIxODB4IN88US=> NWDweHJ2W0GQR1XS
ES4 NITHSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvYcFJHUUN3ME21MlUyOzh7IN88US=> M4fOPHNCVkeHUh?=
GCT NH3FVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTVwNU[4OVYh|ryP M2r4WnNCVkeHUh?=
NCI-H1048 NITSUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj5TWM2OD13Lkm3Nlc{KM7:TR?= NGrlTJFUSU6JRWK=
NCI-SNU-1 NY[0b|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfncGxKSzVyPU[uNFIzKM7:TR?= M1u0V3NCVkeHUh?=
ES7 NX7Nc2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXpb2pKSzVyPU[uNFM2PzdizszN MlT3V2FPT0WU
SW982 NEnMco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXYXot2UUN3ME22MlA6OTN5IN88US=> NXvLb4RIW0GQR1XS
L-363 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTZwM{O5O|Qh|ryP MorFV2FPT0WU
HT-1080 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvSUFhKSzVyPU[uOFk3QDNizszN Mmn4V2FPT0WU
HAL-01 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonNTWM2OD14LkWxNFkh|ryP NGPwW3RUSU6JRWK=
NB14 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13qOGlEPTB;Nj62OFA{QSEQvF2= MlG1V2FPT0WU
EW-13 NEK5fIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfxOnloUUN3ME22Mlc4PDJ2IN88US=> MXvTRW5ITVJ?
NY MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33OUGlEPTB;Nj65OFYxPSEQvF2= M4nRZXNCVkeHUh?=
NCI-SNU-5 NIfudXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLlTWM2OD15LkGwOFM{KM7:TR?= MXXTRW5ITVJ?
MS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLqTWM2OD15LkG3OFk1KM7:TR?= NFHUVI1USU6JRWK=
EW-16 M{\FPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HySGlEPTB;Nz6zNVg3OSEQvF2= NHjBOlhUSU6JRWK=
LU-65 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[4dWgzUUN3ME23MlQ5PDF5IN88US=> NGXiNm1USU6JRWK=
HGC-27 NFf5[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W1Z2lEPTB;Nz63NlE4OyEQvF2= MWjTRW5ITVJ?
CTB-1 NWrMcVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HOWGlEPTB;Nz63OlE4PSEQvF2= NIfjZo5USU6JRWK=
5637 M1zkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lw[mlEPTB;Nz65Nlg3KM7:TR?= NYW2XYR7W0GQR1XS
U251 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zuRmlEPTB;Nz65OFAyPiEQvF2= NH\JUZhUSU6JRWK=
HOS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfWem5KSzVyPUiuNlMxODdizszN NUTpdmQ4W0GQR1XS
DOHH-2 M{W1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD16LkKzOVgh|ryP MlTwV2FPT0WU
EW-1 NVL3fIFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HU[mlEPTB;OD6zNFA5QCEQvF2= NI[y[GxUSU6JRWK=
BV-173 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwNUW1OEDPxE1? M3HD[XNCVkeHUh?=
8-MG-BA NYH3bGx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTCTWM2OD16Lk[4PVg5KM7:TR?= MnrwV2FPT0WU
NB69 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LYS2lEPTB;OD63NFkzOSEQvF2= M3zLfnNCVkeHUh?=
NCI-H69 M13xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkTWM2OD17LkmwPVYyKM7:TR?= M1L0bnNCVkeHUh?=
RS4-11 NHjBb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjMXY1KSzVyPUGxMlIzODhizszN MmjsV2FPT0WU
ONS-76 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;RNmlEPTB;MUGuNlk1PyEQvF2= Mon1V2FPT0WU
SF539 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFzLkS4PFkh|ryP NImyR2dUSU6JRWK=
HuO-3N1 NGn0V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliyTWM2OD1zMT61O|k3KM7:TR?= MmfhV2FPT0WU
NCI-H1651 M4nadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF{LkOxNVUh|ryP NUPZXHBTW0GQR1XS
KARPAS-45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{njbWlEPTB;MUKuN|c3KM7:TR?= NILTNIJUSU6JRWK=
SK-NEP-1 NYXPN4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF{LkS2NFkh|ryP NUHzTmhEW0GQR1XS
LAMA-84 NFn2epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLEd3Q2UUN3ME2xN{4yODl3IN88US=> NXjkVHlKW0GQR1XS
NCI-H1155 NF;XeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF|LkK4OVYh|ryP MVvTRW5ITVJ?
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL5XGxKSzVyPUGzMlQ1PSEQvF2= M3yySXNCVkeHUh?=
QIMR-WIL MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTF|Lke4NVQh|ryP M3PwRnNCVkeHUh?=
H9 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDIcYdNUUN3ME2xN{45PDd3IN88US=> NYKycW1GW0GQR1XS
SK-MEL-1 NUnQTWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD1zMz65N|Q4KM7:TR?= M1rlU3NCVkeHUh?=
HD-MY-Z MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LYRmlEPTB;MUSuNFY{PyEQvF2= NEnUfm1USU6JRWK=
TI-73 M{TzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrvVZQzUUN3ME2xOE4zOzV4IN88US=> NVHofItFW0GQR1XS
JVM-3 NEXxZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP5TWM2OD1zNT61O|E3KM7:TR?= MkO1V2FPT0WU
D-247MG NHPRZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmxeJlDUUN3ME2xOU42QTNizszN MVHTRW5ITVJ?
VA-ES-BJ NIPKU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS1ZnpKSzVyPUG1MlYxQTdizszN MlHtV2FPT0WU
NOS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF3Lk[1NlIh|ryP NUfP[oUyW0GQR1XS
MOLT-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF4Lke1NkDPxE1? MXfTRW5ITVJ?
Mo-T NWHFcGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF5LkC4OFkh|ryP NGTMPJhUSU6JRWK=
NCI-H1770 NXL0d|d6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZWIwzUUN3ME2xO{4yPTR|IN88US=> MYnTRW5ITVJ?
COLO-320-HSR NYjUbnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF5LkG4Nlch|ryP MXLTRW5ITVJ?
TE-12 NVzPN3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\ob5hKSzVyPUG3MlcxPTRizszN MVPTRW5ITVJ?
NCI-H82 NFXwfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv4fVBKSzVyPUG3Mlg4OjhizszN NWTEcpJ4W0GQR1XS
NEC8 NGDpeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki0TWM2OD1zOD6xN|E3KM7:TR?= NHi2OnpUSU6JRWK=
HSC-3 NGD4XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfadopKSzVyPUG4Mlc1OTRizszN NFLFOYRUSU6JRWK=
NCI-H1092 NHTPWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHzRoRKSzVyPUG4Mlc2QTVizszN MVfTRW5ITVJ?
NCI-H292 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T2VWlEPTB;MUmuNFQ5QSEQvF2= NUf6W41qW0GQR1XS
L-428 NX:w[XFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD1TWM2OD1zOT61OVkh|ryP MYLTRW5ITVJ?
LU-134-A NUDZcmxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvFWG9KSzVyPUG5MlU4OiEQvF2= M{TCbXNCVkeHUh?=
GI-ME-N NFm4NGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O3Z2lEPTB;MUmuOVc1PyEQvF2= MX\TRW5ITVJ?
ALL-PO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnTRmtKSzVyPUG5MlU6PzJizszN MWXTRW5ITVJ?
D-283MED M3nMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX1TWM2OD1zOT65NVUh|ryP NVXPdmhFW0GQR1XS
D-423MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXjUm9KSzVyPUG5Mlk6PjdizszN MXzTRW5ITVJ?
CAKI-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn6TWM2OD1{MD6yNlE6KM7:TR?= MVTTRW5ITVJ?
ETK-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL3O5B[UUN3ME2yNE4zPjF3IN88US=> M1nMSnNCVkeHUh?=
G-402 M3m4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPrTWM2OD1{MD61N|M1KM7:TR?= M2D3[nNCVkeHUh?=
HL-60 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qwN2lEPTB;MkGuNVYyOyEQvF2= NUjpN|VFW0GQR1XS
A2058 M1vNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDFd|ZKSzVyPUKxMlQ1PzdizszN MVTTRW5ITVJ?
CHP-212 M1nyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j3SGlEPTB;MkGuPVA2OSEQvF2= Mn;4V2FPT0WU
KY821 NFHweYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T4OGlEPTB;MkGuPVc2KM7:TR?= M4jLVXNCVkeHUh?=
TYK-nu NVjjVI92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXizNVZrUUN3ME2yNk4xPjVzIN88US=> NWLhPIFqW0GQR1XS
JVM-2 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0PIFSUUN3ME2yNk4zQTh|IN88US=> NFTwO4ZUSU6JRWK=
KU812 M1HBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jrT2lEPTB;MkKuO|MyOiEQvF2= MojSV2FPT0WU
MKN28 NIjYd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTyNGJKSzVyPUKyMlkxOTVizszN MlHKV2FPT0WU
ECC10 NHfONGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3GXHhKSzVyPUKzMlc1OSEQvF2= MULTRW5ITVJ?
BHT-101 NXq3ZYl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ThcWlEPTB;MkSuNFAxQCEQvF2= M2T4bXNCVkeHUh?=
DU-4475 NV7KS2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL5TWM2OD1{ND6zN|M4KM7:TR?= NHrTelZUSU6JRWK=
769-P MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfFTWM2OD1{ND64OFY3KM7:TR?= NY\x[2F3W0GQR1XS
HEC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ3LkS0OUDPxE1? NESzcZhUSU6JRWK=
MOLT-13 MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;GfmlEPTB;MkWuOVM{OSEQvF2= MknVV2FPT0WU
8505C MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[1fHdKSzVyPUK2MlQ6PzdizszN MVTTRW5ITVJ?
GB-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\XTWM2OD1{Nj63NVc3KM7:TR?= NIL2VlNUSU6JRWK=
SF126 NYXYdHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ4Lke2OFgh|ryP NE\4bHVUSU6JRWK=
A4-Fuk MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXFTWM2OD1{Nz6xNlcyKM7:TR?= MnnyV2FPT0WU
OVCAR-8 M2nxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnRbYVLUUN3ME2yO{4yPTN7IN88US=> MV7TRW5ITVJ?
NCI-H1304 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTvSIhmUUN3ME2yO{42PCEQvF2= M3\NTXNCVkeHUh?=
GR-ST NY[2RYlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uTWM2OD1{OD6wOFch|ryP Mn;HV2FPT0WU
G-401 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXETWM2OD1{OD61NFk3KM7:TR?= MoC2V2FPT0WU
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml22TWM2OD1{OD61OlUyKM7:TR?= M2nxOHNCVkeHUh?=
DBTRG-05MG M2\NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizSoVTUUN3ME2yPE46OjB2IN88US=> MmfPV2FPT0WU
YKG-1 M13yO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD1{OT64Olgh|ryP Mmf1V2FPT0WU
GAMG NEj4fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ7Lkm5N{DPxE1? NIOwRXBUSU6JRWK=
HCT-116 NUnkcYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7Qbo9KSzVyPUOwMlA2PDhizszN MmiyV2FPT0WU
S-117 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f2[WlEPTB;M{GuNlI2PyEQvF2= NXPm[o4{W0GQR1XS
NCI-H1693 M3rmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G1WmlEPTB;M{OuOlU1OiEQvF2= NEXmT|dUSU6JRWK=
A427 NVLteGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN|Lkm5O|Yh|ryP NYT3VoRTW0GQR1XS
HT-29 NW\l[lU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m0XmlEPTB;M{SuOlA{OiEQvF2= MYHTRW5ITVJ?
P12-ICHIKAWA MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HzbWlEPTB;M{SuO|Q6OSEQvF2= MlXjV2FPT0WU
CAL-51 M2nEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITGdW9KSzVyPUO1MlA4ODlizszN NWrDd2dCW0GQR1XS
Ramos-2G6-4C10 NF7aUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkixTWM2OD1|NT6yOFI2KM7:TR?= MmfFV2FPT0WU
SCH MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32yeWlEPTB;M{[uOFE4PCEQvF2= MVTTRW5ITVJ?
SK-MEL-24 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN4LkmwOFQh|ryP MnPPV2FPT0WU
SW1573 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLFTWM2OD1|OD63NlE3KM7:TR?= Mnn3V2FPT0WU
BALL-1 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\RWW1lUUN3ME2zPU4zOTJ7IN88US=> NF\mbVVUSU6JRWK=
BE-13 M2jlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPkTWM2OD1|OT6zNlkh|ryP NYXQOotWW0GQR1XS
GI-1 M2CwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7PTWM2OD1|OT64OlQ4KM7:TR?= MkfYV2FPT0WU
GOTO M4XNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K5WWlEPTB;M{muPVE{QSEQvF2= M3;XPHNCVkeHUh?=
A673 M3i5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLVTJV7UUN3ME20NU4xOzR|IN88US=> NGf5dIxUSU6JRWK=
KG-1 NV7Ud2NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTYTWM2OD12Mz6zPVQh|ryP NWfqd5RUW0GQR1XS
GP5d MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTxTWM2OD12ND6wOlY3KM7:TR?= NW\ENYV2W0GQR1XS
MFM-223 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnlTWM2OD12ND6xNlI5KM7:TR?= NGTI[3dUSU6JRWK=
OAW-42 NXXNfGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorKTWM2OD12ND6yOlQ{KM7:TR?= MUfTRW5ITVJ?
C8166 NXHRN4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjtTWM2OD12NT6wPFIzKM7:TR?= MVjTRW5ITVJ?
LU-99A NYizWIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGOW4{UUN3ME20Ok4yOzJ{IN88US=> M1rTcnNCVkeHUh?=
NCI-H23 NGS1Zm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\aZ2lEPTB;NE[uNVc5PSEQvF2= NGj4[FhUSU6JRWK=
HO-1-N-1 M4fnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLzTWM2OD12Nz6wPVk5KM7:TR?= NIW1dVJUSU6JRWK=
A3-KAW NFHibZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XjeGlEPTB;NEeuNVAxPyEQvF2= NIH0TlVUSU6JRWK=
CGTH-W-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfpTWM2OD12Nz61NFY6KM7:TR?= NHXPcJZUSU6JRWK=
DJM-1 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXwSYdKSzVyPUS3MlU1OTNizszN NV;iOXZNW0GQR1XS
A101D NHzIOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR5Lk[zOVch|ryP NHj2NoNUSU6JRWK=
BB30-HNC MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrWR5pKSzVyPUS4MlMxPzJizszN NYGxSI1tW0GQR1XS
T98G MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f0TWlEPTB;NEiuOFY{OyEQvF2= MnTSV2FPT0WU
NCI-H1573 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzXTWM2OD12OT60OFYzKM7:TR?= NU\UTlgzW0GQR1XS
MEG-01 NYTuc2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7RTI5KSzVyPUS5Mlc1OTFizszN MnqyV2FPT0WU
WM-115 NIqzVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTR7LkmyNlIh|ryP NGXWTZZUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Olaparib有效作用于Brca1-/-;p53-/- 乳腺肿瘤 (每天按50 mg/kg剂量腹腔注射),但是对 HR缺陷的Ecad-/-;p53-/-乳腺肿瘤没有效果。Olaparib作用于携带肿瘤的鼠没有剂量限制毒性。[3] Olaparib已经用于治疗BRCA突变的肿瘤, 比如卵巢癌,胸腺癌,前列腺癌。此外,Olaparib抑制ATM缺陷的肿瘤细胞具有选择性,说明Olaparib可作为治疗ATM突变的淋巴肿瘤的潜在试剂。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

体外独立酶实验:

通过PARP-1实验测定PARP-2抑制活性,实验在96孔板上进行,PARP-2特定抗体与重组PARP-2蛋白结合。加入3H-NAD+DNA测定PARP-2活性。 冲洗后,加入闪烁剂测定3H-渗透的核糖基化。通过AlphaScreen实验测定端锚聚合酶-1, 实验中HIS标签重组TANK-1蛋白和生物素化的NAD+ 在384孔Proxi板上温育。 加入Alpha 磁珠,与HIS和生物素化的标签结合,产生邻近信号,测定信号消失的比例来计算TANK-1抑制活性。
细胞实验:

[1]

+ 展开
  • Cell lines: 胸腺癌细胞系SW620结肠, A2780卵巢,HCC1937,Hs578T,MDA-MB-231,MDA-MB-436,和T47D
  • Concentrations: 1到300 nM
  • Incubation Time: 7-14天
  • Method:

    通过成株实验测定Olaparib毒性。Olaparib溶于DMSO中,用培养基稀释。细胞接种在六孔板上,过夜使粘附。然后加入不同浓度Olaparib,温育7-14天。计算存活菌落,测定IC50值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 携带Brca1-/-;p53-/-乳腺癌的 K14cre;Brca1F/F;p53F/F
  • Formulation: 50 mg/mL储存在含10% 2-羟丙基-β-环糊精/PBS的DMSO中
  • Dosages: 50 mg/kg
  • Administration: 按10 μL/g剂量腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 434.46
化学式

C24H23FN4O3

CAS号 763113-22-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • 回答:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • 问题 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • 回答:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)供应商 | 采购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)价格 | Olaparib (AZD2281, Ku-0059436)生产 | 订购Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID